• The shares of the cancer therapy producer were buffeted by FDA approval and dilution.
• Their Cesium-131 based brachytherapy solutions show a lot of promise, not only in combating prostate cancer where they get most of their revenues.
• The company has a chance to scale up with the FDA approval, but they will have to speed up to warrant the current share price.

Source: IsoRay Has Exciting Prospects – IsoRay, Inc. (NYSEMKT:ISR) | Seeking Alpha